KP136 (AL136)
(Synonyms: AL136) 目录号 : GC32001KP136 (AL136) (AL136) 是一种口服有效的抗过敏剂。
Cas No.:76239-32-2
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kinase experiment: | The sensitized peritoneal exudate cells are taken from rats weighing 140-180 g with a 24-hr latent period, into which anti-DNP-As serum (0.1 mL) is injected in traperitoneally and suspended at a density of 5×104 mast cells/mL in PBS, pH 7.2 [137 mM NaCl, 2.7 mM KCl, 1 mM CaCl2, 1 mM MgCl2 6H20, 5.6 mM glucose and 5% (v/v) of 0.1 M phosphate buffer]. For histamine release assay, 2.5 mL of the cell suspension are mixed with 0.5 mL of PBS containing a test compound and DNP-As. The mixture is incubated at 37°C for 10 min and centrifuged at 670× g for 10 min. The histamine contents of the precipitate and the supernatant are measured by the fluorometric method. The mast cell degranulaton assay is carried out. The sensitized cell suspension (50 μL) is mixed with 50 μL of PBS containing a test compound and DNP-As in a Bellco micro-slide culture chamber. The chamber is incubated at 37°C for 10 min, and the cells on microscope slides are fixed and stained by the addition (100 μL/chamber) of 20% neutral formalin solution containing 0.2% toluidine blue. The proportion of mast cells undergoing degranulation is assessed for about 200 mast cells under microscopic observation[1]. |
Animal experiment: | Pigs[1] The trachea is taken from male guinea pigs, weighing 500-590 g, that are sacrificed by bleeding and then cut into 1.5 mm wide to make tracheal rings. Five specimens are tied at cartilage sites crossing each smooth muscle layer. This preparation is incubated in Tyrode's solution at 37°C, which is bubbled with 95% O2/5% CO2. The tension change of the tracheal muscle preparation is recorded through an isotonic transducer. C4C and KP136 in 0.5% KHCO3 or isoproterenol in saline is added cumulatively to the Tyrode's solution at a 1/200 volume. Relaxation percentage is calculated from the maximum relaxation value (100%) produces by re placement of the bathing medium with Tyrode's solution containing no CaCl2. |
References: [1]. Kuriyama K, et al. Antiallergic effects of 4-[2-oxo-3-(1H-tetrazol-5-yl)-2H-chromen-8-yloxy]-bu tyric acid. Jpn J Pharmacol. 1989 Jun;50(2):111-8. |
KP136 is an orally effective antiallergic agent. The IC50 is 76.1 μg/mL for histamine release and 63 ug/mL for degranulation.
KP136 (0.01 μg/mL) inhibits this histamine release and degranulation in a dose-dependent manner, confirming that it is an inhibitor of mast cell activation. The IC50 is 76.1 μg/mL for histamine release and 63 ug/mL for degranulation[1].
C4C at 0.2 mg/kg produces an equipotent effect to 1 mg/kg KP136 (KP-136) or 5 mg/kg DSCG. However, C4C is less effective by the oral route because it only produces a maximum inhibition of about 35% even at the high dose of 100 mg/kg, whereas KP136 shows an overt inhibitory effect of about 66% at the oral dose of 2 mg/kg. On the other hand, KP136 (1 mg/kg, i.v.) also remarkably inhibits 5-h homologous PCA, having an activity similar to that of C4C[1].
[1]. Kuriyama K, et al. Antiallergic effects of 4-[2-oxo-3-(1H-tetrazol-5-yl)-2H-chromen-8-yloxy]-bu tyric acid. Jpn J Pharmacol. 1989 Jun;50(2):111-8.
Cas No. | 76239-32-2 | SDF | |
别名 | AL136 | ||
Canonical SMILES | O=C1C(C2=NNN=N2)=CC3=CC=CC(OCCCCCC)=C3O1 | ||
分子式 | C16H18N4O3 | 分子量 | 314.34 |
溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.1813 mL | 15.9063 mL | 31.8127 mL |
5 mM | 0.6363 mL | 3.1813 mL | 6.3625 mL |
10 mM | 0.3181 mL | 1.5906 mL | 3.1813 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。